Acumen Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Northwestern University

Wei-Qin Zhao

Paul J Shughrue

Weirong Wang

Fubao Wang

Alexander McCampbell

Renee C Gaspar

Ningyan Zhang

William F Goure

Min Xu

Mary J Savage

Abigail L Wolfe

Alexander Mccampbell

William L Klein

Grant A Krafft

Nigyan Zhang

Franz F Hefti

This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.

Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

The present invention relates to antibodies that bind amyloid &#x3b2;-derived diffusible ligands, also known as ADDLs. The antibodies of the invention are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs.

Anti-ADDL monoclonal antibody and uses thereof

This invention is a selective A&#x3b2; oligomer kit and immunoassay method capable of reliably and sensitively detecting A&#x3b2; oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A&#x3b2; oligomer antibodies, as capture and detection antibodies, to detect and quantify A&#x3b2; oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.

Antibodies, kit and method for detecting amyloid beta oligomers

The present invention relates to methods for enhancing the cellular uptake and clearance of soluble oligomeric A&#x3b2; peptide assemblies from the environment surrounding both neuronal and non-neuronal cells. Oligomeric A&#x3b2; peptide assembly uptake and clearance is achieved via an agent that enhances insulin receptor signaling. Such ADDL uptake enhancers represent effective anti-ADDL therapeutics for use in the therapeutic treatment and/or prophylactic treatment of diseases including Alzheimer's disease, Down's syndrome, and the like, in which compromised nerve cell function is linked to the formation and/or the activity of soluble oligomeric A&#x3b2; peptide assemblies, also known as ADDLs, and ADDL-related assemblies.

Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance

Growing community of inventors

North Wales, PA, United States of America

Wei-Qin Zhao